DRD5 and colitis: SKF-38393 (a D1R subfamily agonist with a higher affinity to D5R, see Table 3) administration, at the dose of 10 mg/kg via i.p., reduced the clinical signs of DSS-induced colitis in WT mice, observed as reduced weight loss, a lower DAI score, reduced shortening of the colon length, less histopathological findings, and lower serum levels of the cytokines TNFα, IL-6, and CCL2, whereas those effects were impaired in Drd5−/− mice [38].